These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 30021908)
1. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Johnson DB; Bordeaux J; Kim JY; Vaupel C; Rimm DL; Ho TH; Joseph RW; Daud AI; Conry RM; Gaughan EM; Hernandez-Aya LF; Dimou A; Funchain P; Smithy J; Witte JS; McKee SB; Ko J; Wrangle JM; Dabbas B; Tangri S; Lameh J; Hall J; Markowitz J; Balko JM; Dakappagari N Clin Cancer Res; 2018 Nov; 24(21):5250-5260. PubMed ID: 30021908 [No Abstract] [Full Text] [Related]
2. [Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma]. Liu HQ; Zou BQ; Wang SY Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):782-788. PubMed ID: 29136692 [No Abstract] [Full Text] [Related]
3. Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy. Iga N; Otsuka A; Hirata M; Kataoka TR; Irie H; Nakashima C; Matsushita S; Uchi H; Yamamoto Y; Funakoshi T; Fujisawa Y; Yoshino K; Fujimura T; Hata H; Ishida Y; Kabashima K Cancer Sci; 2019 Nov; 110(11):3434-3441. PubMed ID: 31509303 [TBL] [Abstract][Full Text] [Related]
4. Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma. Santos-Briz A; Cañueto J; Carmen SD; Barrios B; Yuste M; Bellido L; Ludeña MD; Román C Am J Dermatopathol; 2021 Jun; 43(6):423-428. PubMed ID: 33395045 [TBL] [Abstract][Full Text] [Related]
5. The role of the immunoescape in colorectal cancer liver metastasis. Takasu C; Yamashita S; Morine Y; Yoshikawa K; Tokunaga T; Nishi M; Kashihara H; Yoshimoto T; Shimada M PLoS One; 2021; 16(11):e0259940. PubMed ID: 34797860 [TBL] [Abstract][Full Text] [Related]
6. Impact of sidedness of colorectal cancer on tumor immunity. Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001 [TBL] [Abstract][Full Text] [Related]
7. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197 [TBL] [Abstract][Full Text] [Related]
8. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Schalper KA; Carvajal-Hausdorf D; McLaughlin J; Altan M; Velcheti V; Gaule P; Sanmamed MF; Chen L; Herbst RS; Rimm DL Clin Cancer Res; 2017 Jan; 23(2):370-378. PubMed ID: 27440266 [TBL] [Abstract][Full Text] [Related]
9. Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Mills AM; Peres LC; Meiss A; Ring KL; Modesitt SC; Abbott SE; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Wallace K; Schildkraut JM Int J Gynecol Pathol; 2019 Mar; 38(2):157-170. PubMed ID: 29485423 [TBL] [Abstract][Full Text] [Related]
10. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663 [No Abstract] [Full Text] [Related]
11. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]
12. Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Bellone S; Buza N; Choi J; Zammataro L; Gay L; Elvin J; Rimm DL; Liu Y; Ratner ES; Schwartz PE; Santin AD Clin Cancer Res; 2018 Jul; 24(14):3282-3291. PubMed ID: 29351920 [No Abstract] [Full Text] [Related]
13. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524 [TBL] [Abstract][Full Text] [Related]
14. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832 [TBL] [Abstract][Full Text] [Related]
15. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Taube JM; Klein A; Brahmer JR; Xu H; Pan X; Kim JH; Chen L; Pardoll DM; Topalian SL; Anders RA Clin Cancer Res; 2014 Oct; 20(19):5064-74. PubMed ID: 24714771 [TBL] [Abstract][Full Text] [Related]
16. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients. Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892 [TBL] [Abstract][Full Text] [Related]
17. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174 [No Abstract] [Full Text] [Related]
18. Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. Mandarano M; Bellezza G; Belladonna ML; Van den Eynde BJ; Chiari R; Vannucci J; Mondanelli G; Ludovini V; Ferri I; Bianconi F; Del Sordo R; Cagini L; Albini E; Metro G; Puma F; Sidoni A Virchows Arch; 2019 Feb; 474(2):159-168. PubMed ID: 30448912 [TBL] [Abstract][Full Text] [Related]
19. HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling. Arkhypov I; Özbay Kurt FG; Bitsch R; Novak D; Petrova V; Lasser S; Hielscher T; Groth C; Lepper A; Hu X; Li W; Utikal J; Altevogt P; Umansky V J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113897 [TBL] [Abstract][Full Text] [Related]
20. A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma. Girault I; Adam J; Shen S; Roy S; Brard C; Faouzi S; Routier E; Lupu J; Warren S; Sorg K; Ong S; Morel P; Scoazec JY; Vagner S; Robert C Clin Cancer Res; 2022 Feb; 28(3):518-525. PubMed ID: 34785583 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]